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Female positive/male negative HIV-serodiscordant couples express a desire for children
and may engage in condomless sex to become pregnant. Current guidelines recommend
antiretroviral treatment in HIV-serodiscordant couples, yet HIV RNA viral suppression may
not be routinely assessed or guaranteed and pre-exposure prophylaxis may not be readily
available. Therefore, options for becoming pregnant while limiting HIV transmission should
be offered and accessible to HIV-affected couples desiring children.
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Methods
A prospective pilot study of female positive/male negative HIV-serodiscordant couples
desiring children was conducted to evaluate the acceptability, feasibility, and effectiveness
of timed vaginal insemination. Eligible women were 18–34 years with regular menses. Prior
to timed vaginal insemination, couples were observed for two months, and tested and
treated for sexually transmitted infections. Timed vaginal insemination was performed for up
to six menstrual cycles. A fertility evaluation and HIV RNA viral load assessment was offered
to couples who did not become pregnant.
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Findings
Forty female positive/male negative HIV-serodiscordant couples were enrolled; 17 (42.5%)
exited prior to timed vaginal insemination. Twenty-three couples (57.5%) were introduced to
timed vaginal insemination; eight (34.8%) achieved pregnancy, and six live births resulted
without a case of HIV transmission. Seven couples completed a fertility evaluation. Four
women had no demonstrable tubal patency bilaterally; one male partner had decreased
sperm motility. Five women had unilateral/bilateral tubal patency; and seven women had an
HIV RNA viral load (� 400 copies/mL).

Conclusion
Timed vaginal insemination is an acceptable, feasible, and effective method for attempting
pregnancy. Given the desire for children and inadequate viral suppression, interventions to
support safely becoming pregnant should be integrated into HIV prevention programs.

Introduction
With the increased availability of antiretroviral (ARV) therapy, HIV-infected individuals are
living with HIV as a chronic disease [1]. Those with stable infection are focused on achieving
full integration into their communities and living productive lives, including having children
[2–4]. In the early stages of the HIV epidemic, however, HIV-infected individuals were advised
against having children, a decision that was fueled by fear and ethical concerns associated with
the risk of HIV transmission in the setting of attempted pregnancy [3].
In sub-Saharan Africa (SSA), women disproportionately represent the majority of new HIV
infections, which occur within stable sexual relationships [5, 6]. It is estimated that 44% of couples in Kenya are HIV-serodiscordant and that HIV transmission within serodiscordant partnerships may account for more than 60% of new HIV infections [7, 8]. HIV infection does not
change an individual’s reproductive desires [1]. An estimated 20–50% of HIV-infected individuals still want to have children [7];. In SSA, comprehensive reproductive counseling and
services that support safely becoming pregnant are currently limited for HIV-affected individuals and couples desiring children [1, 9]. The provision of reproductive services as harmreduction techniques allow couples to achieve their reproductive goals while preventing HIV
transmission to the uninfected sexual partner and developing fetus [10]. In female-positive/
male-negative (♀+/♂-) HIV-serodiscordant couples, timed vaginal insemination (TVI) of
semen during the fertile period of the menstrual cycle, as well as consistent male condom use
that essentially eliminates the risk of sexual HIV transmission when attempting pregnancy are
easy, safe, convenient, and inexpensive reproductive options [9, 11, 12]. Although current
guidelines recommend ARVs in HIV-serodscordant partnerships through ARV initiation in
the HIV-infected partner or pre-exposure prophylaxis (PrEP) in the uninfected partner, HIV
RNA viral suppression is not guaranteed and may not be routinely assessed among patients on
ARVs; and PrEP is not widely available or acceptable to uninfected partners [13–15]. Therefore, other methods of safely becoming pregnant for HIV-affected couples desiring children
should be evaluated and integrated into comprehensive HIV prevention and reproductive
health services [1, 16, 17].
We evaluated the acceptability, feasibility, and effectiveness of TVI as a safer method of
becoming pregnant among ♀+/♂- HIV-serodiscordant couples in Kisumu, Kenya. We
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conducted a prospective pilot study in Kisumu, in the Nyanza region of Western Kenya, where
the HIV prevalence is 18.7% [18]. Nationally, the HIV prevalence is higher among women
(6.9%) than men (4.2%) [18]. The primary outcomes of this study were acceptability, feasibility, and effectiveness of TVI amongst ♀+/♂- HIV-serodiscordant couples planning a pregnancy in Kisumu, Kenya. The secondary outcomes were the incidence of sexual and/or
vertical HIV transmission, adherence to the TVI procedures, the incidence of infertility in
those who did not become pregnant with TVI, and prevalence of viremia among HIV-infected
women unable to become pregnant after six cycles.

Methods
Study population and sampling
Study participants were recruited from six Family AIDS Care & Education Services (FACES)supported and two other HIV care and treatment clinics in the Kisumu area. FACES provides
care to 77,553 clients at 131 sites throughout Western Kenya as of December 2014 [19]. Eligible study participants were ♀+/♂- HIV-serodiscordant couples who self-reported the following: 1) monogamous relationship and disclosure of HIV status to the male sexual partner; 2)
childbearing desires; 3) sexually active (at least three encounters per month) with expressed
ability to consistently use male condoms; and 4) the women were aged 18–34 years. Couples
were excluded if: 1) the woman was pregnant at the time of screening, enrollment, or during
the observation period; 2) they self-reported sterilization or conditions associated with infertility in the couple; 3) they self-reported use of medications thought to be teratogenic at the time
the study was designed (e.g., efavirenz); or 4) World Health Organization (WHO) clinical
stage 3 or 4 disease.
Recruitment of eligible study participants occurred in four ways. First, study recruitment
flyers were posted in the waiting rooms at the healthcare facilities in Dholuo and Kiswahili for
interested HIV-infected individuals to initiate a call. Second, healthcare providers at the
FACES-supported HIV care and treatment clinics were informed of the study and eligibility
criteria during an informational session led by the Study Coordinator. The healthcare providers were instructed to refer eligible HIV-infected women to the Study Coordinator for further
screening and possible enrollment. Third, the FACES HIV care and treatment clinic database
was queried for HIV-infected women aged 18–34 who were clients at one of the six recruitment sites. The medical charts of these women were reviewed by the study staff to assess the
HIV status of their most recent and/or documented partner, current method of contraception,
prior pregnancies, and living children. Women fulfilling eligibility criteria at the time of chart
review were identified and approached at their next clinic visit by study staff to discuss the
study and their possible interest in participating. Finally, the most successful recruitment strategy employed the delivery of health talks focused on pregnancy planning, with emphasis on
TVI, in the waiting room of the healthcare clinic. Any woman identified by any of the four
recruitment strategies was instructed to discuss the study with her HIV-uninfected male partner and present with him as a couple for a study information session. After the information
session, couples with a continued interest in study participation were scheduled for a screening
visit to assess for possible underlying infertility in either partner, review the study procedures,
and complete the medical chart abstraction of the HIV-infected female. ♀+/♂- HIV-serodiscordant couples fulfilling all eligibility criteria with an expressed interest in study participation
and willingness to comply with the study procedures were offered study enrollment. Study participants were contacted by phone and visited at home in order to encourage continued study
participation and decrease loss to follow-up.
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Data collection and validation
Questionnaires were developed and administered in English, Dholuo, or Kiswahili via audio
computer-assisted self-interview (ACASI) software to assess the participants’ ease of use with
the TVI procedures and adherence to the study protocol throughout the study period (S1
Appendix). Female participants also agreed to collection of clinical and demographic data at
the time of study enrollment via medical chart review. These data were abstracted from their
medical records using a study-specific data collection form. After enrollment, couples were
observed for a minimum of two months to monitor the woman’s menstrual cycle and provide
couples’ counseling and support to enhance consistent condom use. During the observation
period, women were taught to identify their fertile period using the calendar method, along
with assessment of cervical mucus consistency. The female partner presented on a monthly
basis during the observation period with their menstrual calendars, which noted the days of
menstrual bleeding and the nature of their vaginal secretions. The estimated mean menstrual
cycle length was used to prospectively estimate the fertile window, approximately five days, for
TVI for up to six menstrual cycles. The male partner presented at three months after enrollment or prior to initiation of the TVI procedures to complete the ACASI questionnaire and
screening for sexually transmitted infections (STI). The study coordinator also conducted a
routine monthly home visit to assess the couple’s well-being, emphasize condom use, and collect a self-administered vaginal swab, if indicated.
A self-administered vaginal swab was collected on a monthly basis at the time of a clinic or
home visit outside of the estimated fertile period to assess the presence of prostate specific antigen (PSA), a surrogate marker of semen exposure. A positive PSA test noted on the ABAcard
p30 (Abacus Diagnostics, West Hills, California) suggested condomless sexual intercourse
within the prior 24 hours. A monthly urine pregnancy test (QuickVue One-Step hCG Urine
Test, Quidel Corporation, San Diego, California, USA) was also performed. A rapid HIV test
was performed by finger prick using Determine HIV rapid kit (Alere Medical Co. Ltd, Japan)
every three months in the male partner and positive test results were confirmed by Unigold
HIV rapid kit (Trinity Biotech PLC, Ireland) in accordance with the Kenyan National Guidelines for HIV voluntary counseling and testing [20].
Prior to TVI initiation, couples were screened for STIs (i.e. Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis (Gen-Probe Aptima assay by Gen-Probe Inc., San
Diego, California, USA), and Treponema pallidum (Rapid Plasma Reagin, Becton-Dickinson,
Baltimore, Maryland, USA; T. pallidum Haemagglutination Assay (TPHA, Randox Laboratory
LTD, United Kingdom) and treated, if indicated. Women were also screened for bacterial vaginosis with microscopy and symptoms of STIs at their routine study visits–monthly in women
and every three months in the male partner. A positive STI test resulted in empiric treatment
of the couple. A test of cure was performed at least three weeks after treatment before continuation with the TVI procedures.
During the periovulatory period, couples were taught to collect semen using a water-based
lubricated condom after timed sexual intercourse two days prior to ovulation, on the estimated
day of ovulation, and two days after ovulation due to the estimation of ovulation, for up to six
cycles or until pregnancy was noted. Used syringes were stained with methylene blue to detect
the presence of vaginal epithelial cells. The presence of vaginal epithelial cells, which was used
as an internal validation of TVI compliance [21].
A fertility evaluation was offered to couples who did not achieve pregnancy within six
cycles—a semen analysis in the male after three days of sexual abstinence and a hysterosalpingo-contrast-sonography (HyCoSy) in the female to assess tubal patency and uterine and
endometrial factors, and to quantify ovarian reserve (i.e. antral follicle count) in the early
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follicular phase [22]. Semen analysis was performed according to WHO standards [23]. All
HyCoSy assessments to assess female fertility were performed by a single provider (AM), thus
reducing potential inter-observer variance. The male partner was also screened for chlamydia,
gonorrhea, HIV, trichomoniasis, and prior chlamydia infection with an anti-chlamydial antibody. HIV RNA viral load (COBA AmpliPrep/COBAS TaqMan1 HIV-1 Test, v2.0 Roche
Diagnostics, Mannheim, Germany) was also assessed in the HIV-infected female.

Study measurements
For this analysis, demographic and clinical characteristics assessed from ACASI surveys conducted at study enrollment include: prior ARV use, history of STIs and pelvic inflammatory
disease, treatment of STIs, number of prior pregnancies, number of living children, current
method of contraception, frequency of condom use, and whether or not male partners were
circumcised. Characteristics assessed at enrollment from the female’s medical chart review
include: age, occupation, education, presence of an AIDS-defining illness, WHO disease stage,
current ARV use, body mass index, CD4 count, and date of HIV diagnosis.
Acceptability and feasibility of the TVI procedures were assessed monthly in females and
every three months in males using ACASI during the intervention phase with the following
questions: “How easy was it for you and your partner to follow the instructions for vaginal
insemination and perform the procedure during the past month,” on a scale of 1 to 6 (e.g. 1-very
easy, 2-easy, 3-somewhat easy, 4-a little difficult, 5-very difficult, or 6-impossible) and “In the
past month, how would you describe how well you followed the instructions and procedures for
the study?” on a scale of 0 to 3 (0-poor, 1-fair, 2-well, or 3-very well). The effectiveness of TVI
was assessed using incidence of pregnancy among female participants who initiated the TVI
intervention. HIV transmission was assessed with rapid HIV tests among male participants
and the HIV status of infants at nine months of age born to women who became pregnant during the TVI intervention phase, as self-reported by the mother. Adherence to the TVI procedures was measured by a positive test for vaginal epithelial cells on syringes used for the TVI
procedures.

Data analysis
Demographic and clinical characteristics of study participants, as well as incident pregnancy
were described using frequencies, proportions, and medians when appropriate. Kaplan-Meier
analyses were used to estimate time to pregnancy for all women who initiated the TVI intervention; women were censored from this analysis at the time they exited the study. We utilized
repeated measures generalized linear models to predict means and assess change in the acceptability and feasibility measures over time during the TVI intervention, including terms to
examine the interaction of pregnancy and time. Change over time was considered significant
at an alpha level of 0.05. Birth outcomes and neonatal HIV status were self-reported by the
HIV-infected female. Descriptive statistics were used to characterize the outcome of the fertility evaluations.
Data collected in ACASI were extracted to Microsoft Excel Version 2007 (Microsoft Inc.,
Redmond, Washington, USA). Excel was also used to collect and store baseline measures
abstracted from female study participants’ charts. These data were imported into SAS Version
9.3 (SAS Institutes, Cary, North Carolina, USA) for further data management and analysis.

Ethical considerations
Ethical approval was obtained from the Kenya Medical Research Institute (KEMRI) Ethical
Review Committee and from the University of California, San Francisco, and the University of
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Michigan institutional review boards. The study procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and
national) and the Helsinki Declaration of 1975, as revised in 2000. All study participants provided written informed consent in their preferred language (i.e. Kiswahili, Dholuo, or English).
This study was registered on ClinicalTrials.gov (NCT01468753).

Results
Demographics
Forty ♀+/♂- HIV-serodiscordant couples were enrolled in the study (Fig 1).
Seventeen couples were exited for the following reasons: dissolution of the relationship
(n = 4), voluntary cessation of study participation (n = 2), HIV seroconversion of the male
partner (n = 2), irregular menses (n = 2), and loss to follow-up (n = 7). Sixty percent (n = 24)
of women denied a prior history of STIs (N. gonorrhoeae, C. trachomatis, T. vaginalis, and herpes simplex virus infection). All women denied a history of pelvic inflammatory disease. One

Fig 1. Study participants. ♀+/♂- Female positive/male negative.
https://doi.org/10.1371/journal.pone.0212656.g001
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couple was diagnosed and treated for T. vaginalis infection prior to TVI. In another couple,
the male partner was diagnosed with T. pallidum and treated according to Kenyan guidelines;
they were later diagnosed and treated for C. trachomatis infection at an outside facility. After
one cycle of TVI, the aforementioned couple was discontinued from the study due to their
inability to comply with the study protocol and procedures. All couples had a negative test of
cure prior to initiating the TVI procedure. Other sexually-associated infections that were diagnosed in our cohort included: bacterial vaginosis (n = 2), candida vaginitis (n = 1), and genital
condylomas (n = 1).
The median age of women was 29 years (IQR 24–32). Approximately 53% (n = 21) of
women were employed outside of the home, 35% (n = 14) completed secondary or post-secondary education, 62.5% (n = 25) were on ARVs at enrollment, and 72.5% (n = 29) selfreported consistent condom use at baseline (Table 1). Twenty-three couples (57.5%) were
introduced to TVI.

Acceptability and feasibility of TVI
The estimated perceived mean ease of use during the first TVI cycle was described as “easy” or
“somewhat easy” (2.96, 95% CI 2.4–3.5) by study participants. Ease of use did not differ by sex
(p = 0.20), nor did it change over the course of the intervention by pregnancy status (p = 0.69).
Amongst women introduced to TVI, 96.7% (n = 267 positive syringes per 276 cycle days) of
their TVI syringes had evidence of vaginal insertion per staining of the syringes.

Effectiveness of TVI
Eight (34.8%) of the 23 women introduced to TVI became pregnant, which resulted in six live
births without a case of HIV transmission to the neonate or partner. Two cases of neonatal
demise occurred; one of a term (estimated gestational age of 39 weeks) neonate due to respiratory distress and the other due to complications of prematurity (estimated gestational age of
22 weeks). Accounting for loss to follow-up, our Kaplan-Meier analysis estimates that 36%
(95% CI: 20–59%) of women introduced to TVI would become pregnant within 150 days,
approximately five months, of TVI initiation (Fig 2).

Non-pregnant couples
The 15 couples who did not become pregnant within six months were eligible for a fertility
and HIV RNA viral load evaluation. Fourteen couples consented; seven couples completed
both male and female fertility assessments; and 12 women completed viral load testing. Four
women had bilateral fallopian tube occlusion, one male partner had decreased sperm motility,
and five women had unilateral or bilateral fallopian tube patency. Seven (50%) women had an
HIV RNA viral load (� 400 copies/mL) (Table 2). The cost for a female and male fertility evaluation in Kenyan Shillings (KES) (1 USD � 90 KES) was KES 13,300 (USD 147) and KES
8,880 (USD 99) respectively.

Discussion
Acceptability, feasibility, and effectiveness of TVI
TVI is an acceptable, feasible, and effective method for ♀+/♂- HIV-serodiscordant couples
attempting to become pregnant. The time to pregnancy achieved during this study mirrors
that of HIV-unaffected couples who have no evidence of infertility [24, 25]. Study participants
reported ease with the TVI procedures with support from clinical providers during the study
period. In this pilot study, we employed the use of focused instructional aids for the TVI
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Table 1. Incidence and predictors of pregnancy at enrollment (n = 40).
Variables

Pregnant, n = 8 (%)

Non-pregnant, n = 32 (%)

FEMALE PARTNER FACTORS
Age–Median (Q1 –Q3)

29 (22.0–32.0)

27 (23.5–31.0)

Work outside the home

3 (43)

18 (60)
17 (71)

Level of Education
Some Primary

0 (0)

Some secondary

3 (43)

2 (8)

Some post-secondary

4 (57)

5 (21)

AIDS-Defining Illness
Yes

0 (0)

4 (12)

No

7 (100)

28 (88)

WHO stage (initiation of care)
1

5 (62)

19 (59)

2

3 (38)

8 (25)

3

0 (0)

3 (9)

4

0 (0)

2 (6)

Current ARV use

4 (50)

21 (66)

Prior ARV usea

4 (50)

21 (66)

History of STI (gonorrhea, chlamydia, trichomonas, HSV)

2 (25)

12 (38)

History of PIDa
Yes

0 (0)

0 (0)

No

8 (100)

32 (100)

BMI at enrollment–Median (Q1- Q3)

24.1 (22.2–26.8)

21.9 (19.1–24.6)

CD4 count/mm3 at enrollment median (Q1- Q3)

479 (447.5–739.5)

480.5 (367–574.5)

0

1 (12)

5 (16)

1

2 (25)

9 (28)

2

3 (38)

12 (38)

3+

2 (25)

6 (19)

0

3 (38)

10 (31)

1

3 (38)

10 (31)

2

1 (12)

8 (25)

3+

1 (12)

4 (12)

Years since HIV diagnosis median (Q1 –Q3)

4.3 (1.3–7.4)

2.2 (1.0–5.5)

Number of prior pregnanciesa

Number of living childrena

Current method of contraception
None

0 (0)

11 (36)

Oral tablets

0 (0)

3 (10)

Depo Provera1 (DMPA)

0 (0)

3 (10)

Other/traditional family planning

8 (100)

13 (43)

Condom use at enrollment
100%

8 (100)

21 (66)

50–99%

0 (0)

8 (25)

<50%

0 (0)

3 (9)

Age–Median (Q1-Q3)

33.5 (25.5–39.0)

33.5 (28.5–35.0)

History of STIa

2 (25)

10 (32)

Treated for STIa

2 (25)

7 (22)

MALE PARTNER FACTORS

(Continued )
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Table 1. (Continued)
Variables

Pregnant, n = 8 (%)

Circumciseda

2 (25)

Non-pregnant, n = 32 (%)
17 (53)

0

3 (38)

10 (31)

1

3 (38)

8 (25)

2

1 (12)

8 (25)

3+

1 (12)

6 (19)

Number of living childrena

a

Condom use at enrollment
100%

6 (75)

23 (72)

50–99%

2 (25)

7 (22)

<50%

0 (0)

2 (6)

ARV–antiretroviral therapy; WHO–World Health Organization; STI–sexually transmitted infection;
DMPA–Depot medroxyprogesterone acetate; HSV–herpes simplex virus; PID–pelvic inflammatory disease
Indicates data was self-reported by patient

a

https://doi.org/10.1371/journal.pone.0212656.t001

procedures, education and counseling sessions for couples eligible for TVI, and dedicated clinical staff to support couples using TVI as a reproductive method. Where appropriate, we recommend that clinical program directors implement these best practices to enhance the
acceptability, feasibility, and effectiveness of TVI as a reproductive option for ♀+/♂- HIV-serodiscordant couples. Although we conducted our pilot study in Kisumu, Kenya, our findings
are applicable to low-resource environments throughout the world and has high impact on
empowering women in HIV-serodiscordant partnerships with an affordable and readily accessible reproductive option.

Programmatic lessons from the field
Prior to implementation of TVI, programmatic costs should be considered due to STI screening and treatment, pregnancy and HIV testing, home visits and calls, and clinical staff time. In
our cohort, all couples who became pregnant did so in one to three menstrual cycles. In order
to decrease the distress associated with an inability to become pregnant and possible underlying infertility, healthcare providers should consider minimizing TVI attempts to no more than
three menstrual cycles. As reproductive programs supporting pregnancy in HIV-serodiscordant couples are being developed and implemented, translation of research procedures should
be considered. In the implementation phase, the use of PSA and syringe staining to assess consistent condom use may not be warranted.
All HIV-infected individuals in serodiscordant partnerships should be on ARVs in order to
prevent HIV infection to the HIV-uninfected partner and unborn child. Furthermore, clinical
support should be offered to HIV-affected couples planning a pregnancy to ensure HIV RNA
viral suppression in the HIV-infected partner. We followed the existing national Kenya HIV
treatment guidelines at the initiation of our study in 2012; however, these guidelines have
changed, and all HIV-infected individuals in a HIV-serodiscordant partnership are currently
eligible for ARVs regardless of CD4 count [26]. Although ARV initiation in the HIV-infected
partner is protective against HIV transmission [27], couples should also be informed that HIV
transmission may still occur [28, 29] due to poor ARV adherence, possible presence of HIVresistant mutations [30], or condomless sex too soon after initiation of ARVs, which may limit
the ability to achieve HIV viral suppression.
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Fig 2. Kaplan-Meier plot–time to pregnancy (days) (n = 23a). aPatients were only included in the analysis if an intervention start date was available. Follow-up time was
calculated as time from intervention start date to conception date or intervention start date to study exit date, whichever occurred first.
https://doi.org/10.1371/journal.pone.0212656.g002

Lessons following the fertility evaluations and recommendations
The findings of our fertility assessment highlight the need for providers to consider a fertility
evaluation in couples preparing to attempt pregnancy prior to making recommendations on a
safe reproductive method. Cost may be one of the significant barriers to a full fertility assessment; this should be addressed with pragmatic low-cost approaches that prioritize making a
prompt definitive diagnosis and subsequently triaging couples to effective low-cost fertility
interventions. Our fertility assessment was limited to diagnosis only and could only include
referral for the provision of clinical services to address any identified fertility problem. Even
though such information was informative, it underlines the agony of making a diagnosis and
coming to an abrupt end-point as appropriate assisted reproduction techniques are either
unavailable or currently unaffordable to most HIV-affected couples in low-resource settings.
Strategies should also be considered to support and encourage male partners to complete their
fertility evaluations, since a full couple’s evaluation is most meaningful in developing an
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Table 2. Fertility evaluation findings.
Assessment

Result (n = 14)

Comment

HyCoSy

Bilateral/Unilateral tubal
patency (n = 5)

Additional laparoscopic assessment and possibly in vitro
fertilization in women with bilateral tubal occlusion

Bilateral tubal occlusion
(n = 4)
Inability to tolerate
procedure (n = 2)
Withdrew consent for
evaluation (n = 3)
AFC
HIV RNA Viral Load
(copies/mL)
Other Pelvic
Pathology

Range: 7–20
b

a

All had reasonable ovarian reserve

Detectable in 7 women,
range: 1,355–66,321

Consider ARV adherence and attempted pregnancy in the
setting of a detectable HIV RNA viral load

Endometrial polyp(s) and
fluid (n = 2)

Consider additional hysteroscopic assessment for
endometrial pathology

Submucosal fibroid in
endometrial cavity (n = 1)
Unilateral dermoid cyst
(n = 1)
Semen analysis
(interpreted per WHO
standards)

Normal (n = 8)
c

Borderline (n = 1)

Consider cultural and personal challenges to semen
analysis

Declined semen analysis
(n = 5)

HyCoSy–hysterosalpingo-contrast-sonography; AFC–antral follicle count
a

Normal AFC >10 follicles on two ovaries combined

b

All men were HIV-negative
Suitable for intra-uterine insemination

c

https://doi.org/10.1371/journal.pone.0212656.t002

appropriate plan of care for HIV-serodiscordant couples attempting pregnancy. Public health
strategies, even in low-resource settings, must be put in place to address fertility interventions
for couples in low socio-economic groups. A simplified fertility awareness questionnaire, such
as FertiSTAT [31], may be used to assess for possible underlying fertility problems to reduce
the risk of HIV exposure with unnecessary attempts at becoming pregnant. For those who are
identified at higher risk for a fertility problem, through the use of a questionnaire, a clinical fertility assessment should be recommended and offered.

Limitations
We encountered a few limitations stemming from a low uptake amongst those eligible for
study participation and a 42% study drop-out rate. These limitations may be due to the novelty
of TVI, requirement of disclosure of HIV status and male partner engagement, and sociocultural stigma associated with assisted reproduction.

Future directions
There is an apparent research gap in the implementation and provision of safe reproductive
options for HIV-serodiscordant couples desiring children. Our findings suggest that implementation studies are warranted to inform widespread integration of TVI into HIV care and
treatment programs in low-resource settings. HIV-serodiscordant couples planning to have
children should be supported in shared decision-making with a range of reproductive options
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that may include treatment as prevention, timed condomless intercourse, TVI, PrEP, and
assisted reproductive technology services.
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